DGAP-News: VisionHealth GmbH
/ Key word(s): Product Launch
VisionHealth adds Clinical Trial Function to Kata(R)App supporting and optimizing inhalation therapy of chronic lung diseases
Munich (Germany), November 4, 2021 - VisionHealth GmbH, a pioneer in digital therapeutics (DTx) for the inhaled treatment of chronic lung diseases, today announced the launch of its Kata(R) Clinical app offering, a new version of the Kata(R) app with extended features. With Kata(R) Clinical, VisionHealth aims to create new possibilities for sponsors and contract research organizations (CROs) conducting clinical trials in chronic respiratory diseases, leveraging the Kata(R) technology to enhance the participants' experience and improve study outcomes at the same time. "Kata(R) Clinical may take both data and patient management in respiratory trials to a new level. Based on the customized adaptation to the specific needs of a study, data collection and management can be conducted more efficiently and are less error-prone due to automation," said Dr. Sabine Häußermann, CEO and founder of VisionHealth GmbH. "We are convinced that study outcomes will significantly benefit from enhanced patient interactions. Kata(R) can ensure accurate drug dosing through correctly performed inhalation, positively impact adherence, and ultimately improve therapeutic outcomes while reducing overall trial costs: with Kata(R), less patients allow for the same statistical power." The newly launched Kata(R) Clinical allows remote collection of high-quality data, including clinical parameters and conditions. Further, the app allows for monitoring patients' adherence, the review of individual inhalation history and disease progression parameters, as well as guidance to correct inaccurate administration of inhaled drugs. Kata(R) Clinical can provide a direct link between the study centers and each patient, allowing the centers to supervise and monitor the patient in real-time and ensuring that no appointments in the study center are missed. Furthermore, the system supports automatic data upload into the electronical case report form (eCRF compliant) and is thus compatible with most common study data management systems. In order to match individual clinical trial requirements, the functions included in Kata(R) Clinical can be customized to each partner's specific needs, such as diary functions, daily questionnaires or medication reminders. Kata(R) Clinical complies with the criteria of good clinical praxis (GCP) and meets all technical, regulatory and data protection regulations, qualifying it for the use in clinical studies. The Kata(R) platform builds on VisionHealth's proprietary artificial intelligence (AI) algorithm to monitor and support correct inhalator usage for the therapy of chronic lung diseases. The incorrect administration of inhaled drugs is a common problem of chronic respiratory patients, with different studies reporting error rates as high as between 32 and 100 %.[1],[2],[3],[4],[5] Incorrect inhalation and resulting underdosing of drugs cause a high unmet medical need and higher rates of complications and exacerbations in the most prevalent chronic lung diseases, Asthma and Chronic Obstructive Pulmonary Disease (COPD).[6] Especially in COPD, every exacerbation is known to cause an irreversible loss of lung function.[7] Better disease control with fewer exacerbations and consequently lower hospitalization rates could lead to massive cost savings for public health systems.[6] Worldwide, Kata(R) could support the therapy of approximately 250 million patients suffering from chronic respiratory diseases, with an estimated 8.9 million cases alone in Germany.[8],[9] About VisionHealth About Kata(R)
A modified Kata(R) app for Clinical Trials (Kata(R) Clinical) combines data and patient management to enhance the participants' experience and improve study outcomes at the same time. Based on the customized adaptation to the specific needs of a study, data collection and management can be conducted more efficiently and are less error-prone due to automation. Contact Media Contact
04.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
1246225 04.11.2021